CX3CL1 and central nervous system cancer: Also, an engineered peptide receptor-antagonist of fractalkine (Hermand et al., 2008) mediated ERK phosphorylation in primary glioma cells comparable to the recombinant soluble peptide (Figure 4A, lower part).